-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12

Benzinga·08/06/2026 12:13:52
Listen to the news
Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.